|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/2887 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61K2039/545 | (2013.01) |
| (11) | Number of the document | 3697818 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18804720.3 |
| Date of filing the European patent application | 2018-10-19 | |
| (97) | Date of publication of the European application | 2020-08-26 |
| (45) | Date of publication and mention of the grant of the patent | 2024-11-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2018/038924 |
| Date | 2018-10-19 |
| (87) | Number | WO 2019/017499 |
| Date | 2019-01-24 |
| (30) | Number | Date | Country code |
| 201762574297 P | 2017-10-19 | US |
| (72) |
WENGER, Michael , CH
MOBASHER, Mehrdad , US
LIN, Chin-Yu , US
|
| (73) |
F. Hoffmann-La Roche AG ,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBINUTUZUMAB |
| TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBINUTUZUMAB |